首页 > 抗体蛋白 > 抗体
PE anti-human IFN-γ Antibody
产品名称:
PE anti-human IFN-γ Antibody
产品类别:
抗体
产品编号:
506506
产品应用:
506506
[价格]
规格 价格 库存
25tests ¥ 1236 1

产品详情

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee, Baboon, Cynomolgus, Rhesus, African Green, Pigtailed Macaque, Sooty Mangabey
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
E. coli-expressed recombinant human IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Flow Cytometry2: The fluorochrome-labeled B27 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-? -producing cells within mixed cell populations. For intracellular cytokine staining protocol, please visit www.biolegend.com and click on the support section.
Neutralization1,3,6,7: The Ultra-LEAF? Purified antibody (Endotoxin <0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for neutralization of human IFN-? bioactivity (Cat. No. 506531).

Application References

(PubMed link indicates BioLegend citation)
  1. Favre C, et al. 1989. Molec. Immunol. 26:17. (Neut)
  2. Kaur A, et al. 2002. J Virol. 76:3646.
  3. Abrams J, et al. 1992. Immunol. Rev. 127:5. (Neut)
  4. Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag.
  5. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  6. Acosta-Rodriguez EV, et al. 2007. Nat. Immunol. 9:942-9. (Neut)
  7. Gangur V, et al. 1998. FASEB J. 12:705-13. (Neut)
Product Citations
  1. Mo Y, et al. 2022. Front Immunol. 12:799896. PubMed
  2. Rappazzo CG, et al. 2020. bioRxiv. . PubMed
  3. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  4. Bilich T, et al. 2021. Cancer Discov. 11:1982. PubMed
  5. Ali A, et al. 2020. J Infect Dis. 222:853. PubMed
  6. Xun X, et al. 2021. Am J Transl Res. 13:4360. PubMed
  7. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  8. Bauer J, et al. 2022. Nat Commun. 13:6401. PubMed
  9. Das J, et al. 2021. Med (N Y). 2:1269. PubMed
  10. Lübke M, et al. 2020. J Exp Med. 217:00:00. PubMed
  11. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  12. Rice TF, et al. 2021. EBioMedicine. 72:103612. PubMed
  13. Heitmann JS, et al. 2021. Nature. Online ahead of print. PubMed
  14. Minassian AM, et al. 2021. Med (N Y). 2:701. PubMed
  15. Bilich T, et al. 2021. Science Translational Medicine. 13(590):. PubMed
  16. Punik J, et al. 2021. Cell Reports. 35(13):109320. PubMed
  17. Such L, et al. 2020. J Clin Invest. 4266:130. PubMed
  18. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  19. Grace PS, et al. 2021. Front Immunol. 12:679973. PubMed
  20. Xu C, et al. 2020. Methods Mol Biol. 2108:159. PubMed
  21. Imura Y, et al. 2020. JCI Insight. :5. PubMed
  22. Duque JSR, et al. 2022. Nat Commun. 13:3700. PubMed
  23. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  24. Atyeo C, et al. 2022. Nat Commun. 13:3571. PubMed
  25. Crump NT, et al. 2021. Cell Reports. 35(6):109101. PubMed
  26. Zhong M, et al. 2022. Cell Death Dis. 13:671. PubMed
  27. Luo Z, et al. 2021. Int J Mol Sci. 22:. PubMed
  28. Niu M, et al. 2021. Cell Reports. 36(8):109611. PubMed
  29. Jeong HO, et al. 2022. iScience. 25:105358. PubMed
  30. Li L, et al. 2022. JCI Insight. 7:. PubMed
  31. Cimen Bozkus C, et al. 2021. STAR Protoc. 2:100758. PubMed
RRID
AB_315439 (BioLegend Cat. No. 506506) AB_315440 (BioLegend Cat. No. 506507)

Antigen Details

Structure
Cytokine; dimer; 20-25 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2
Gene ID
3458 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线